About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
  FY 2016 - 2017
  
  April 2017
  March 2017
  February 2017
  January 2017
  December 2016
  November 2016
  October 2016
  September 2016
  August 2016
  July 2016
  June 2016
  May 2016
  April 2016
     
 
Disclosure to Stock Exchange

  December 2018
19 Dec Meetings conducted with Institutional Investors/Research Analysts Download Pdf
10 Dec Meetings conducted with Institutional Investors/Research Analysts Download Pdf
03 Dec Change in name of Registrar & Share Transfer Agent- Karvy Computershare Private Limited to Karvy Fintech Private Limited Download Pdf
  November 2018
30 Nov Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU Download Pdf
27 Nov Meetings conducted with Institutional Investors/Research Analysts. Download Pdf
26 Nov Change in the name & contact details of Key Managerial Personnel under the Policy for Determination of Materiality of disclosures Download Pdf
23 Nov Meetings conducted with Institutional Investors/Research Analysts. Download Pdf
21 Nov Meetings conducted with Institutional Investors/Research Analysts. Download Pdf
16 Nov Investor Presentation for Quarter ended September 30, 2018 Download Pdf
16 Nov Meetings conducted on November 16, 2018 with Institutional Investors/Research Analysts. Download Pdf
15 Nov Meetings conducted with Institutional Investors/Research Analysts. Download Pdf
12 Nov Meetings conducted on November 12, 2018 with Institutional Investors/Research Analysts. Download Pdf
12 Nov Biocon's Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations Download Pdf
9 Nov Meetings conducted on November 8, 2018 and November 9, 2018 with Institutional Investors/Research Analysts. Download Pdf
  October 2018
25 Oct Biocon Q2FY19 Earnings PressRelease Download Pdf
19 Oct Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab Download Pdf
08 Oct Intimation of Board Meeting scheduled on Thursday, October 25, 2018. Download Pdf
  September 2018
27 Sep Meetings conducted on September 26, 2018 and September 27, 2018, with Institutional Investors/Research Analysts. Download Pdf
22 Sep Biocon’s Drug Substance Facility in Bangalore completes US FDA inspection with no observations Download Pdf
21 Sep Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim - Press Release Download Pdf
20 Sep Meetings conducted on September 19, 2018 and September 20, 2018, with Institutional Investors/Research Analysts Download Pdf
11 Sep Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015. Download Pdf
11 Sep Meetings conducted on September 10, 2018, with Institutional Investors/Research Analysts Download Pdf
10 Sep Meetings conducted on September 07, 2018, with Institutional Investors/Research Analysts Download Pdf
07 Sep Meetings conducted on September 06, 2018, with Institutional Investors/Research Analysts. Download Pdf
06 Sep Meetings conducted on September 05, 2018, with Institutional Investors/Research Analysts Download Pdf
05 Sep Meetings conducted on September 04, 2018, with Institutional Investors/Research Analysts Download Pdf
03 Sep Appointment of Key Managerial Personnel Download Pdf
03 Sep Investor Presentation Announcement for Quarter ended June 30, 2018 Download Pdf
  August 2018
28 Aug Meeting and teleconference conducted on August 27, 2018 and on August 28, 2018 respectively, with Institutional Investors/Research Analysts Download Pdf
23 Aug Meeting and teleconference conducted on August 23, 2018 with Institutional Investors/Research Analysts Download Pdf
16 Aug Meeting conducted on August 15, 2018 with Institutional Investors/Research Analysts Download Pdf
14 Aug Meeting conducted on August 13, 2018 with Institutional Investors/Research Analysts Download Pdf
09 Aug Meeting conducted on August 08, 2018 with Institutional Investors/Research Analysts Download Pdf
06 Aug Meeting conducted on August 06, 2018 with Investors/Research Analysts Download Pdf
03 Aug Teleconference conducted on August 03, 2018 with Investors/Research Analysts Download Pdf
01 Aug Teleconference conducted on July 31, 2018 with Investors/Research Analysts Download Pdf
  July 2018
28 July Announcement on appointment of Mr. Bobby Kanubhai Parikh as Independent Director Download Pdf
28 July Proceedings of Annual General Meeting including Voting Results and Scrutinizerís Report Download Pdf
26 July Audited Financial Results (Standalone and consolidated) for Q1FY19 Download Pdf
26 July Outcome of the Board Meeting held on 26 July 2018 Download Pdf
26 July Biocon Q1FY19 Earnings PressRelease Download Pdf
05 July Intimation of Board Meeting for approving unaudited Q1 financials Download Pdf
04 July Company Statement: Biocon's Sterile Drug Product facility receives EU GMP Certification Download Pdf
  June 2018
27 June Intimation regarding Meeting with Investor Download Pdf
23 June Biocon’s Sterile Drug Product facility Receives EIR from USFDA Download Pdf
22 June Intimation regarding Teleconference with Investor Download Pdf
05 June Meeting conducted on 4th & 5th of June 2018 with Institutional Investors/Research Analysts. Download Pdf
05 June U.S. FDA approves Mylan and Biocon's FulphilaTM (pegfilgrastim-jmdb), the first Biosimilar to Neulasta Download Pdf
04 June Tata Memorial Hospital team presents Biocon’s Nimotuzumab study results at American Society of Clinical Oncology (ASCO) Annual Meeting 2018 Download Pdf
02 June Biocon and Mylan Press Release pertaining to presenting new data to American society of Clinical Oncology (ASCO) Download Pdf
  May 2018
18 May SAST Regulation 29(2) Download Pdf
18 May Intimation regarding Sale of Equity Shares of the Syngene International Limited Download Pdf
15 May Intimation regarding Analysts/ Institutional Investors meet Download Pdf
09 May Intimation regarding Analysts/ Institutional Investors meet Download Pdf
08 May Intimation regarding Analysts/ Institutional Investors meet Download Pdf
02 May Meeting / teleconference conducted on 1st and 2nd of May 2018 with In stitutional Investors / Research Analysts. Download Pdf
02 May Company Statement on Biocon Regulatory Audit Update Download Pdf
  April 2018
26 April

Audited Financial Results (Standalone and consolidated) for the quarter and year ended 2017-18

Download Pdf
26 April

Outcome of the board meeting held on 26th April, 2018

Download Pdf
26 April

Press Release for the quater and financial year ended 2017-18

Download Pdf
16 April

Proposal to consider recommendation of final dividend

Download Pdf
11 April

Company Statement: Mylan and Biocon seek to accelerate introduction of Adalimumab biosimilar in EU

Download Pdf
05 April

Intimation of Board Meeting Ref: Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Download Pdf
  March 2018
28 Mar

Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine

Download Pdf
27 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
20 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
16 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
15 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
14 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
13 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
02 Mar

Intimation regarding change in Compliance Officer under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.

Download Pdf
02 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
  February 2018
27 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
22 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
21 Feb

Company Statement on US-FDA Inspection at Biocon Malaysia

Download Pdf
20 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
15 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
08 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
08 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
06 Feb

Intimation regarding Analysts/Institutional Investors Meet

Download Pdf
05 Feb

Analysts/Institutional Investors Presentation

Download Pdf
02 Feb

Intimation regarding Analysts/Institutional Investors Meet

Download Pdf
  January 2018
30 Jan

Intimation regarding Analysts/Institutional Investors Meet

Download Pdf
29 Jan

Intimation regarding Analysts/Institutional Investors Meet

Download Pdf
29 Jan

Press Release Media Release

Download Pdf
29 Jan

Biocon Insider Trading Code 2015 - Amended on Jan 24, 2018

Download Pdf
24 Jan

Biocon Document Retention and Archival Policy - Amended on Jan 24, 2018

Download Pdf
24 Jan

Outcome of Board Meeting

Download Pdf
23 Jan

Intimation under Regulation 30 of SEBI Regulations, 2015

Download Pdf
18 Jan

Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

Download Pdf
  December 2017
29 Dec

Biocon and Mylanís Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

Download Pdf
22 Dec

Intimation of Board Meeting

Download Pdf
21 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
20 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
19 Dec

Intimation Regarding Analysts / Institutional Investors Meet

 

Download Pdf
15 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
14 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
13 Dec

Biocon’s Clarification post media reports on “Biocon on the FDA list for not paying facility fee”

Download Pdf
07 Dec

Intimation Regarding Analysts / Institutional Investors Meet

 

Download Pdf
07 Dec

Results of Postal Ballot / eVoting

Download Pdf
07 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
05 Dec

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
01 Dec

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers

 

Download Pdf
01 Dec

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim

 

Download Pdf
  November 2017
23 Nov

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
23 Nov

Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India

Download Pdf
20 Nov

Biocon's Facility Receives EIR with VAI status, Inspection Closed

Download Pdf
15 Nov

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
14 Nov

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
10 Nov

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
08 Nov

Presentation on financial results of the Company for the quarter and half year ended September 30, 2017

Download Pdf
06 Nov

Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA

Download Pdf
06 Nov

Postal Ballot Advertisement

Download Pdf
03 Nov

Postal Ballot Notice to Shareholders

Download Pdf
  October 2017
30 Oct

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
27 Oct

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
25 Oct

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers

Download Pdf
10 Oct

US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim

Download Pdf
  September 2017
27 Sept

Intimation of Board Meeting

Download Pdf
21 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
19 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
18 Sept

Bioconís Facility in Vishakhapatnam completes US FDA Inspection with no observations

Download Pdf
15 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
8 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
7 Sept

Biocon´s Insulins facility in Malaysia Receives EU GMP Compliance Certificate

Download Pdf
6 Sept

JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment

Download Pdf
5 Sept

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
  August 2017
30 Aug

USFDA Target Action Date for Trastuzumab Reset to December 3, 2017

Download Pdf
29 Aug

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
23 Aug

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
22 Aug

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
17 Aug

Intimation Regarding Analysts / Institutional Investors Meet

Download Pdf
16 Aug Company Statement on Status of EMA Dossiers Download Pdf
11 Aug Incorporation of WOS Download Pdf
07 Aug Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
  July 2017
31 Jul Company Statement on USFDA Visit in May/June2017. CAPA is under Implementation Download Pdf
31 Jul Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
14 Jul Press Release titled "FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Bioconís Proposed Biosimilar Trastuzumab" Download Pdf
09 Jul Company's Statement on the outcome of pre-approval inspection audits by French health agency, L'Agence nationale de securite du medicament et des produits de sante (ANSM) on behalf of European Medicines Agency (EMA) Download Pdf
  June 2017
23 Jun Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
20 Jun Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
11 Jun Press Release titled "Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions" Download Pdf
1 Jun Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
  May 2017
11 May Intimation Regarding Analysts / Institutional Investors Meet Download Pdf
10 May Biocon Statement in response to Media Reports on USFDA Form 483s for Biocon Limited. Download Pdf
08 May Newspaper Advertisement For Dispatch Of Postal Ballot Notice And Postal Ballot Form. Download Pdf
05 May Notice Of Postal Ballot Download Pdf
  April 2017
28 Apr Intimation regarding Analyst / Institutional Investor Meet Download Pdf
28 Apr Presentation - Analysts/Institutional Investors Meet Download Pdf
27 Apr  Outcome of Board Meeting Download Pdf
  March 2017
30 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
27 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
15 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
06 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
03 Mar  Biocon's statement in response to Delhi  High Court Interim Order Download Pdf
02 Mar  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  February 2017
27 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
24 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
22 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
16 Feb  USFDA accepts Biologics License Application  (BLA) for Mylan and Biocon's proposed  Biosimilar Pegfilgrastim for Review Download Pdf
14 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
07 Feb  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  January 2017
30 Jan  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
24 Jan  Biocon Q3 FY17 Net Profit Up 65% at Rs 171  Crore; Revenue Rises 32% at Rs 1092  Crore; EBITDA Increases 57% to Rs 324  Crore Download Pdf
11 Jan  U.S. FDA Accepts Biologics License  Application (BLA) for Mylan and Biocon's  Proposed Biosimilar Trastuzumab Download Pdf

  December 2016
27 Dec  Journal of the American Medical Association  (JAMA) Publishes Mylan and Biocon's  Proposed Biosimilar Trastuzumab Phase 3  Data Download Pdf
20 Dec  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
17 Dec  Transfer of shares to Investor Education  and Protection Fund Download Pdf
16 Dec  Disclosure under Regulation 30 of SEBI  (LODR) Regulations, 2015 - Change in Key  Managerial Personnel Download Pdf
13 Dec  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
13 Dec  Disclosure under Regulation 30 of SEBI  (LODR) Regulations, 2015 Download Pdf
06 Dec  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  November 2016
29 Nov  Biocon's Novel Diabetes Education Initiative  for Medical Practitioners 'ABIDE' Awarded  by RSSDI Download Pdf
22 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
17 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
15 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
11 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
09 Nov  Intimation regarding Analysts / Institutional  Investors Meet Download Pdf
08 Nov  Mylan and Biocon Announce U.S. FDA  Submission for Proposed Biosimilar  Trastuzumab Download Pdf
03 Nov  Mylan and Biocon Announce Regulatory  Submission for Insulin Glargine Accepted  for Review by European Medicines Agency Download Pdf
  October 2016
24 Oct  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
20 Oct  Unaudited Financial Results for the quarter  and period ended Sep. 30, 2016
Download Pdf
  September 2016
29 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
23 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
19 Sep  Biocon Appoints Suresh Subramanian as  Head of Branded Formulations (India)  Business Download Pdf
14 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
07 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
01 Sep  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
  August 2016
26 Aug  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
25 Aug  Mylan and Biocon Announce Regulatory  Submission for Proposed Biosimilar  Trastuzumab Accepted for Review by  European Medicines Agency Download Pdf
24 Aug  Intimation regarding Analyst / Institutional  Investor Meet Download Pdf
17 Aug  Intimation regarding Analyst / Institutional  Investor meet Download Pdf
9 Aug  Intimation regarding Analyst / Institutional  Investor meet Download Pdf
2 Aug  Intimation regarding Analyst / Institutional  Investor meet Download Pdf
  July 2016
28 July  Biocon Initiates "Ek Prayaas" Nationwide  Awareness Program on Hepatitis C Download Pdf
21 July  Biocon Reports a Strong Q1FY17
 Revenues at Rs 952 Crore, up by 11 %;  EBITDA Up 15% to Rs 271 Crore
 Net Profit Up 17% at Rs 147 Crore
Download Pdf
21 July  Mylan & Biocon Announce Regulatory  Submission for Proposed Biosimilar  Pegfilgrastim Accepted for Review by  European Medicines Agency Download Pdf
15 July  Biocon's Insulin Glargine Launched in Japan Download Pdf
  June 2016
27 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
24 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
23 Jun  Biocon, Quark Announce Initiation of Pivotal  Phase II/III Study of QPI-1007 in Rare Eye  Disease in India Download Pdf
22 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
16 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
10 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
04 Jun  Mylan and Biocon to Present Phase 3  Trastuzumab Biosimilar Data at the  American Society of Clinical Oncology  (ASCO) Annual Meeting Download Pdf
03 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
01 Jun  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
  May 2016
30 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
26 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
26 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
18 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
12 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
5 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf
3 May  Intimation regarding
 Analyst/Institutional Investor meet
Download Pdf

  April 2016
26 Apr  Biocon Q4FY16 Net Profit at Rs 361 Cr  Revenue Crosses Rs 1,000 Cr; Up 17% FY  16 Revenues up 14% at Rs 3,570 Cr  Net  Profit at Rs 896 CrDownload Pdf
26 Apr  Intimation Regarding Appointment of  Director Download Pdf




 
     
 March 2016
 February 2016
 January 2016
 December 2015
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved